Literature DB >> 17097841

Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms.

J Goole1, F Vanderbist, K Amighi.   

Abstract

This work relates to the development and the in vitro evaluation of sustained-release minitablets (MT), prepared by melt granulation and subsequent compression, which are designed to float over an extended period of time. Levodopa was used as a model drug. The importance of the composition and manufacturing parameters of the MT on their floating and dissolution properties was then examined. The investigation showed that MT composition and MT diameter had the greatest influence on drug release, which was sustained for more than 8h. By using the same formulation, the best floating properties were obtained with 3mm MT prepared at low compression forces ranging between 50 and 100N. Their resultant-weight (RW) values were always higher than those obtained with a marketed HBS dosage form within 13h. When they were filled into gelatin capsules, no sticking was observed. By evaluating the dissolution profiles of levodopa at different pH values, it was found that dissolution profiles depend more on the prolonged-release ability of Methocel K15M than on the pH-dependent solubility of levodopa. Finally, the robustness of the floating MT was assessed by testing the drug release variability in function of the stirring conditions during dissolution tests.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097841     DOI: 10.1016/j.ijpharm.2006.10.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Design of an interpolyelectrolyte gastroretentive matrix for the site-specific zero-order delivery of levodopa in Parkinson's disease.

Authors:  Ndidi C Ngwuluka; Yahya E Choonara; Girish Modi; Lisa C du Toit; Pradeep Kumar; Valence M K Ndesendo; Viness Pillay
Journal:  AAPS PharmSciTech       Date:  2013-03-15       Impact factor: 3.246

2.  3D Printed Mini-Floating-Polypill for Parkinson's Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy.

Authors:  Hellen Windolf; Rebecca Chamberlain; Jörg Breitkreutz; Julian Quodbach
Journal:  Pharmaceutics       Date:  2022-04-25       Impact factor: 6.525

3.  Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation.

Authors:  Kiran Chaturvedi; S Umadevi; Subhash Vaghani
Journal:  Sci Pharm       Date:  2010-09-26

4.  Formulation and evaluation of controlled-release tablet of zolpidem tartrate by melt granulation technique.

Authors:  Shailesh T Prajapati; Amit N Patel; Chhagan N Patel
Journal:  ISRN Pharm       Date:  2011-06-27

5.  Drug release behavior of polymeric matrix filled in capsule.

Authors:  Thawatchai Phaechamud; Wanwilai Darunkaisorn
Journal:  Saudi Pharm J       Date:  2015-05-02       Impact factor: 4.330

Review 6.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

7.  Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease.

Authors:  Masahiro Nomoto; Masahiro Nagai; Noriko Nishikawa; Rina Ando; Yoshifumi Kagamiishi; Koji Yano; Shigeto Saito; Atsushi Takeda
Journal:  eNeurologicalSci       Date:  2018-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.